Peptide Based Imaging Agents for HER2 Imaging in Oncology
Breast cancer continues to be the most lethal cancer type in women and one of the most diagnosed. Understanding Breast cancer receptor status is one of the most vital processes for determining treatment options. One type of breast cancer, human epidermal growth factor receptor 2 (HER2) positive, has...
Main Authors: | Maxwell Ducharme, Suzanne E. Lapi PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi - SAGE Publishing
2020-09-01
|
Series: | Molecular Imaging |
Online Access: | https://doi.org/10.1177/1536012120960258 |
Similar Items
-
Targeting HER2 in Nuclear Medicine for Imaging and Therapy
by: Adriana V. F. Massicano PhD, et al.
Published: (2018-01-01) -
New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology
by: Anna Lucia Tornesello, et al.
Published: (2017-08-01) -
Oncology imaging
by: S.K. Misser, et al.
Published: (2013-06-01) -
Oncology imaging: Diagnosis
by: S.K. Misser, et al.
Published: (2013-08-01) -
Polyethylene glycol-conjugated HER2-targeted peptides as a nuclear imaging probe for HER2-overexpressed gastric cancer detection in vivo
by: Siao-Syun Guan, et al.
Published: (2018-06-01)